Randomized, Open-Label Study Evaluating the Safety and Rate of Bacterial Clearance of Ceftobiprole 500 Milligram Every 8 Hours Compared to Conventional Therapy in the Treatment of Hospitalized Subjects With Staphylococcus Aureus Bacteremia.

Trial Profile

Randomized, Open-Label Study Evaluating the Safety and Rate of Bacterial Clearance of Ceftobiprole 500 Milligram Every 8 Hours Compared to Conventional Therapy in the Treatment of Hospitalized Subjects With Staphylococcus Aureus Bacteremia.

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 19 Feb 2013

At a glance

  • Drugs Ceftobiprole medocaril (Primary)
  • Indications Bacteraemia; Staphylococcal infections
  • Focus Therapeutic Use
  • Sponsors Janssen Pharmaceuticals
  • Most Recent Events

    • 19 Feb 2013 Additional lead trial centre added as reported by ClinicalTrials.gov.
    • 21 Jul 2011 Planned end date (Apr 2009) added as reported by ClinicalTrials.gov.
    • 07 Mar 2008 Status changed from in progress to withdrawn prior to recruitment. This trial has been withdrawn prior to recruitment, according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top